Llewellyn Jalbert1, Adam Elkhaled1, Joanna Phillips2, Hikari Yoshihara1, Radhika Srinivasan1, Gabriela Bourne1, Susan Chang3, Soonmee Cha1, Sarah Nelson1, 4
1Department of Radiology & Biomedical Imaging, University of California - San Francisco, San Francisco, CA, USA; 2Department of Pathology, University of California - San Francisco; 3Department of Neurological Surgery, University of California - San Francisco; 4Department of Bioengineering & Therapeutic Sciences, University of California - San Francisco
Significant survival advantage is conferred to glioma patients harboring mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), resulting in the excessive production of the onco-metabolite 2-hydroxyglutarate (2HG). We aimed to determine whether 2HG could be detected in recurrent low-grade glioma samples using proton High-resolution Magic Angle Spinning (1H HR-MAS) spectroscopy, and to correlate the results with IDH1 mutation status assessed by immunohistochemistry. We have confirmed 2HG presence by 1D and 2D 1H HR-MAS in concordance with IDH1 status; its presence gives rise to a complicated spectral pattern that may be of significant clinical utility as a novel biomarker in glioma.